This inventor holds 4 USPTO granted patents and 10 published patent applications. Top assignee: Emendobio Inc.. Active years: 2023-2026.
Company Filing History:
Years Active: 2023-2026
Title: Innovations of Nurit Meron in CRISPR Technology
Introduction
Nurit Meron is a prominent inventor based in Ramat Gan, Israel. She has made significant contributions to the field of genetic engineering, particularly through her work with CRISPR technology. With a total of three patents to her name, her innovations are paving the way for advancements in genetic research and applications.
Latest Patents
One of her latest patents is the OMNI-103 CRISPR nuclease. This invention provides a non-naturally occurring composition comprising a CRISPR nuclease with a sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1 or a nucleic acid molecule encoding the CRISPR nuclease. Additionally, she has developed the OMNI-59, 61, 67, 76, 79, 80, 81, and 82 CRISPR nucleases. This patent also offers a non-naturally occurring composition comprising a CRISPR nuclease with a sequence having at least 95% identity to the amino acid sequences selected from the group consisting of SEQ ID NOs: 1-8 or a nucleic acid molecule encoding the CRISPR nuclease.
Career Highlights
Nurit Meron is currently associated with EmendoBio Inc., where she continues to innovate in the field of CRISPR technology. Her work is instrumental in developing new tools for genetic editing, which have the potential to revolutionize various applications in medicine and agriculture.
Collaborations
Some of her notable coworkers include Lior Izhar and Liat Rockah, who contribute to the collaborative efforts at EmendoBio Inc. Their combined expertise enhances the research and development initiatives within the company.
Conclusion
Nurit Meron's contributions to CRISPR technology exemplify the impact of innovative thinking in the field of genetic engineering. Her patents reflect a commitment to advancing scientific knowledge and practical applications in genetics.